Valneva SE
Industry Group: Pharmaceuticals
Country/Region: France
Identifier: PAR:VLA
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 270 out of 847
Universe
Global Universe 8557 out of 14948
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Valneva SE |
27.1
Medium
|
270 out of 847 |
Xeris Biopharma Holdings, Inc. |
27.4
Medium
|
283 out of 847 |
Guangdong Hybribio Biotech Co., Ltd. |
27.7
Medium
|
303 out of 847 |
MeiraGTx Holdings Plc |
28.9
Medium
|
354 out of 847 |
Medy-Tox, Inc. |
40
High
|
808 out of 847 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Valneva SE's Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Valneva SE's Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Valneva SE
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.

What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Valneva SE's ESG Risk Rating in the last three years
Highest Controversy Level

Contributing Events

Highest Controversy Events Locations
